AMRI, Shire ink 5-year extension of API supply agreement
AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.
The agreement extends a previously existing agreement between the two companies. The terms of the agreement are confidential.
“We are pleased to extend this agreement with Shire,” said Thomas E. D’Ambra, Ph.D., chairman, president and CEO of AMRI. “Our partnership lays the groundwork for AMRI to be considered by Shire for future development and manufacturing opportunities.”